2025.Dec.19
Corporate
OBI Pharma and TegMine Therapeutics Sign Commercial License Agreement for Glycoprotein-Targeting ADC
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine
TAIPEI, Taiwan, 12/19/2025 — OBI Pharma (4174.TWO) announced that it has entered into an commercial license agreement with TegMine Therapeutics, Inc. (TegMine),
This article is password protected.
To view the content, please enter your password in the field below